Biohaven Ltd. (BHVN)

Publicly reported company facts and saved market data for Biohaven Ltd. (BHVN), with sources and as-of times. Saved data is not a live quote.

Company profile

Biohaven Ltd. (NYSE: BHVN) is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments across immunology, neuroscience, and oncology. Biohaven is advancing an innovative portfolio of therapeutics built on proven drug development experience and multiple proprietary platforms, including Kv7 ion channel modulation for epilepsy; MoDE and TRAP extracellular protein degradation for immunological diseases; next generation ADC platform for oncology; and myostatin inhibition for neuromuscular and metabolic diseases, including obesity.

Company facts

Sector: Health Care
Industry: Pharmaceutical Preparations
Market cap: $2.3B · as of 2026-10-30
Incorporated in: Virgin Islands, British
Company website: www.biohaven.com
Exchange: NYSE

FennEdge notes

Sessions where BHVN appeared in the Small-Cap Daily, newest first: opening gap, day change and the SEC filing or halt stored by the close. Facts with source links.

2026-10-22 #3 top gapper · gap +37.02% · closed +25.02% 8-K Other Biohaven Ltd. filed an 8-K: Regulation FD

BHVN: The FDA Accepted the Resubmission. The High Came at 7:51 a.m.

All Small-Cap Daily editions

Saved quote

Saved snapshot, not a real-time quote. Check the market time before relying on it.

Last reported price: $15.41
Reported change: -6.55%
Reported volume: 3,164,642
Latest market time: 2026-10-30 17:37 ET

Float and shares outstanding

BHVN float references and SEC-reported shares outstanding
Measure	Shares	As of	Source and basis
Float	119,762,613	2026-09-22	Reported by a single source; not cross-checked.
Shares outstanding (O/S)	151,043,781	2026-08-06	SEC 10-Q filing · filed 2026-08-10

Dates are measurement dates, not the time FennEdge retrieved the data. Float references are listed separately; they are not averaged or adjusted for later splits or share issuances.

Dilution timeline

As of 2026-10-24T20:42:42.796981+00:00

2026-08-10 · 10-Q · Periodic report filed
2026-05-04 · 424B5 · Prospectus filed
2026-05-04 · S-3ASR · Shelf registration filed
2025-11-13 · 424B5 · Prospectus filed
2025-11-12 · 424B5 · Prospectus filed
2025-08-15 · 424B7 · Prospectus filed

Parsed share counts, prices and warrant terms require Plus or above. Explore plans

Research this company

FennEdge organizes SEC filings and reported market data. Sign in for additional research and your private trading context.